...
首页> 外文期刊>Histopathology: Official Journal of the British Division of the International Academy of Pathology >Nm23-H1 nuclear expression is associated with a more favourable prognosis in laryngeal carcinoma: Univariate and multivariate analysis
【24h】

Nm23-H1 nuclear expression is associated with a more favourable prognosis in laryngeal carcinoma: Univariate and multivariate analysis

机译:Nm23-H1核表达与喉癌预后更佳相关:单因素和多因素分析

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: To use image analysis and multivariate analysis to investigate the prognostic significance of Nm23-H1 subcellular localization in a large cohort of laryngeal squamous cell carcinomas (LSCCs). Methods and results: Nm23-H1 total and nuclear levels were immunohistochemically determined and calculated with an image analysis system in 104 consecutively operated LSCCs. The mean follow-up was 58.3± 35.1months (median 45months). Total Nm23-H1 levels correlated only with patient stratification by pT (P=0.01). Mean nuclear Nm23-H1 levels were lower in patients with recurrent disease (P=0.01), and disease-free survival (DFS) was longer in patients whose nuclear levels of Nm23-H1 were >2.0% than in those with levels ≤2.0% (P=0.019). On multivariate analysis, Nm23-H1 nuclear expression [hazard ratio (HR) 2.59, P=0.005] and N stage (HR 3.60, P=0.0001) were prognostically significant in relation to DFS. Conclusions: In LSCC, Nm23-H1 nuclear expression may be useful for identifying patients at higher risk of recurrence after treatment and who might be considered for more aggressive therapy. Further investigations are needed before Nm23-H1 can be considered for use in targeted treatments for LSCC.
机译:目的:使用图像分析和多元分析来研究Nm23-H1亚细胞定位在一大批喉鳞状细胞癌(LSCC)中的预后意义。方法和结果:Nm23-H1总和核水平进行了免疫组织化学测定,并通过图像分析系统在104个连续操作的LSCC中进行了计算。平均随访时间为58.3±35.1个月(中位数为45个月)。 Nm23-H1总水平仅与患者通过pT分层相关(P = 0.01)。复发性疾病患者的平均Nm23-H1核平均水平较低(P = 0.01),Nm23-H1的核水平> 2.0%的患者的平均无核生存期(DFS)高于≤2.0%的患者(P = 0.019)。在多变量分析中,Nm23-H1核表达[危险比(HR)2.59,P = 0.005]和N期(HR 3.60,P = 0.0001)在预后方面与DFS相关。结论:在LSCC中,Nm23-H1核表达可能有助于确定治疗后复发风险较高且可能考虑采用更积极治疗的患者。在考虑将Nm23-H1用于LSCC的靶向治疗之前,需要进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号